Clinical trials: High-Risk Prostate Cancer
Prostate Cancer
Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy
This is a phase I study to evaluate the feasibility and safety of using MRI/MRS to identify the dominant intraprostatic lesion (DIL) and to selectively boost the lesion using inverse planned high dose rate (HDR) brachytherapy.
- Trial name
- NCT00807820
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate
The purpose of the study is to assess the safety of four different doses of radiation therapy followed by to surgery to remove prostate tumor.
- Trial name
- NCT00691977
- Testing
- Radiation Therapy followed by prostatectomy
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Prostate Cancer (Adenocarcinoma), Prostate CA
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer.
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
- Trial name
- NCT06636682
- Testing
- FK-PC101, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cellvax Therapeutics Inc
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Prostate Cancer
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
The goal of this clinical research study is to learn if the addition of sunitinib malate (SU011248) to hormone based castration is an effective treatment for shrinking or controlling the tumor before having the prostate removed.
- Trial name
- NCT00329043
- Testing
- LHRH Agonist, Sunitinib Malate, Radical Prostatectomy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)
Two radiation therapy techniques are commonly used for the treatment of intermediate and high risk prostate cancer: brachytherapy and external beam radiation therapy (EBRT). However, both have limitations.
- Trial name
- ASSERT (NCT02594072)
- Testing
- stereotactic ablative radiotherapy, external beam radiation therapy, Zoladex ®
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- University of British Columbia
Prostatic Diseases, Genital Neoplasms, Male
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
The purpose of this research study is to determine the safety and effectiveness of the investigational drug, Ixabepilone, in men with high risk prostate cancer who plan to receive surgery.
- Conditions
- Prostatic Diseases, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Trial name
- NCT00672009
- Testing
- Ixabepilone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Prostate Cancer
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00003645
- Testing
- Flutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
One of the biggest problems facing prostate cancer patients and their treating physicians is who needs to be treated and when. Common clinical and pathological parameters are useful (PSA, Gleason score, etc.) but do not clearly…
- Trial name
- NCT01350180
- Where
- 8 sites in Canada
- Sponsor
- Dr. Tamim Niazi
Prostate Cancer
Experiences With HDR-brachytherapy in Norway
There are 3 articles that will be written about the experience with HDR-brachytherapy (HDR-BT) in patients with high-risk prostate cancer in Norway as part of a doctorial thesis-project.
- Trial name
- NCT03162523
- Testing
- High-Dose Rate Brachytherapy
- Where
- Norway
- Volunteers
- 325 people
- Sponsor
- Oslo University Hospital
Precancerous/Nonmalignant Condition, Prostate Cancer
Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia
RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development or recurrence of cancer. Vitamin E, selenium, and soy protein may be effective in preventing the development of prostate…
- Trial name
- NCT00064194
- Testing
- selenium, soy protein isolate, vitamin E
- Where
- 3 sites in Canada
- Volunteers
- 310 people
- Sponsor
- NCIC Clinical Trials Group
Prostatic Neoplasms
SmartTarget THERAPY
The purpose of this study is to assess how accurately SmartTarget can direct high intensity focused ultrasound (HIFU) to a pre-defined area (cancer) in the prostate.
- Trial name
- NCT02290561
- Testing
- SmartTarget Therapy, MRI, high intensity focused ultrasound (HIFU)
- Volunteers
- 69 people
- Sponsor
- University College, London
Prostate Cancer, Castration-resistant Prostate Cancer
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- ASPIRE-PCa (NCT02066961)
- Where
- 93 sites in Algeria, Argentina and 25 more
- Volunteers
- 1,533 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostatic Carcinoma
Imaging of High Grade Prostate Cancer
Management of prostatic carcinoma varies according to stage of disease. Trans-rectal ultrasound guided biopsy is known to underestimate the degree of tumor due to undersampling and random non-targeted technique.
- Trial name
- NCT02177526
- Testing
- Imaging
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer
3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer
In standard clinical care, the prostate is imaged by magnetic resonance imaging (MRI) which is a procedure to take pictures of body structures by using a strong magnetic field and radio waves.
- Trial name
- NCT01653093
- Testing
- 3-Tesla magnetic resonance imaging (3T MRI), diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- University of Cincinnati
Localised Prostate Cancer, Locally Advanced Prostate Cancer
MRI Guided Transurethral HIFU for Various Prostate Diseases
This study assesses feasibility and safety, the primary outcomes, of MRI guided transurethral high intensity focused ultrasound (HIFU) ablation for prostate diseases (PD).
- Conditions
- Localised Prostate Cancer, Locally Advanced Prostate Cancer, Locally Recurrent Prostate Cancer, Benign Prostatic Hyperplasia
- Trial name
- HIFU-PRO (NCT03350529)
- Testing
- MRI guided transurethral HIFU ablation of prostatic tissue
- Where
- Finland
- Volunteers
- 87 people
- Sponsor
- Turku University Hospital
Prostate Cancer, Treatment
Comparison H-FIRE and Laparoscopic RP in Treating Men With Localized Prostate Cancer
This trial is comparing the functional and oncological outcomes in treating men with prostate cancer between high-frequency irreversible electroporation and laparoscopic radical prostatectomy.
- Trial name
- NCT04278261
- Testing
- Focal therapy(high-frequency irreversible electroporation), laparoscopic radical prostatectomy
- Where
- China
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Shanghai East Hospital
Prostate Cancer
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00023829
- Testing
- bicalutamide, flutamide, releasing hormone agonist therapy
- Where
- Canada
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
PSMA PET/CT vs. mpMRI in Patients With a High Suspicion of Prostate Cancer: a Head to Head, Parallel, Prospective Trial
This is prospective single-arm case-control study designed to compare in parallel PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy ("experimental test") with mpMRI/TRUS fusion prostate biopsy ("standard test") in men…
- Trial name
- PROSPET-BX (NCT05297162)
- Testing
- PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- Istituto Clinico Humanitas
Prostate Cancer
Long-term Better Than Short-term ADT With Salvage RT
A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after…
- Trial name
- LOBSTER (NCT04242017)
- Testing
- Triptoreline
- Where
- 3 sites in Belgium
- Volunteers
- 394 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven